Filament Health Corp. (NEO:FH)
Canada · Delayed Price · Currency is CAD 0.0100
-0.0050 (-33.33%)
May 21, 2025, 3:22 PM EDT
Filament Health Company Description
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada.
The company’s leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin.
It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage.
In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties.
Filament Health Corp. is headquartered in Burnaby, Canada.
Filament Health Corp.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Benjamin Lightburn |
Contact Details
Address: 4475 Wayburne Drive Burnaby, British Columbia V5G 4X4 Canada | |
| Website | filament.health |
Stock Details
| Ticker Symbol | FH |
| Exchange | Cboe Canada |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA31685W1068 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Benjamin Lightburn | Co-Founder, Chief Executive Officer and Chairman |
| Lisa Ranken | Chief Operating Officer |
| Ryan Moss | Chief Science Officer |
| Jonathan Conlin | Corporate Secretary and Director |
| Steven Nguyen CPA | Interim Chief Financial Officer |
| Anna Cordon | Vice President of Marketing and Communications |
| Jeff Fellows | Head of Regulatory |
| Andry Tjahyana | Vice President of Business Development |
| Sara Burke B.A., M.B.A. | Head of Global Partnerships |